智能控制基于脂质的纳米载体,用于微调肠道激素分泌
Yining Xu1,2,3,4, Cécilia Bohns Michalowski1, Jackie Koehler5,6
1Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Université catholique de Louvain, 1200 Brussels, Belgium.
Science advances
|December 13, 2024
概括
脂质纳米载体激活肠道激素的释放,为代谢功能障碍提供了一个新的非侵入性策略. 这种纳米技术方法调节多种内源激素,以获得治疗效益.
科学领域:
- 胃肠道学和内分泌学
- 纳米技术 纳米技术
- 代谢疾病研究研究
背景情况:
- 调节胃肠道激素是代谢功能障碍的一个关键策略.
- 肠内分泌细胞 (EECs) 在肠内分泌功能中起着至关重要的作用.
研究的目的:
- 研究脂质纳米载体调节内源性胃肠道激素释放的潜力.
- 探索纳米技术在治疗代谢功能障碍方面的治疗应用.
主要方法:
- 使用过的小鼠和人类的敲进/敲关肠道器官.
- 使用商业脂质辅助剂配制的脂质纳米载体.
- 在野生型,失糖和肠道Gcg淘汰赛小鼠中研究了效应.
主要成果:
- 脂质纳米载体激活了EECs上的营养敏感受体.
- 证明了GLP-1,GIP和PYY从K和L细胞中的释放.
- 辅助剂类型,配方和纳米载体特性调制生物效应.
结论:
- 纳米技术为代谢功能障碍提供了一个有希望的,非侵入性的治疗方法.
- 通过脂质纳米载体调节多种内源激素是可行的.
- 这一策略提出了一种患者友好且具有成本效益的激素调节方法.
相关概念视频
01:24Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
01:40Hormonal Regulation
43.1K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.1K